Delivery Order SPE2DB24D8003-SPE2DB25FJTUH

Award Date 2/7/25
Potential Completion Date 2/10/25
Potential Value $3.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBQWZ, was issued by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $17,018.46, is a firm fixed-price delivery order for the supply of VRAYLAR 3 MG CAPSULE 30S, a pharmaceutical product. Dakota Drug, Inc. is a key supplier to the DLA, holding a significant single-award Indefinite Delivery Contract (IDC) valued at...
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBQCC, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The $5,192.94 firm fixed price delivery order is for the provision of VRAYLAR 3 MG CAPSULE 30S, a pharmaceutical product. Dakota Drug, Inc. is a significant supplier for the DLA Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) as part of the DLA...
This federal contract award, valued at $4,508.95, was issued by the Defense Logistics Agency (DLA) to prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is for the delivery of VRAYLAR 1.5 MG CAPSULE 30S, a pharmaceutical product, with a completion date of August 28, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program,...
The U.S. Defense Logistics Agency (DLA) has awarded a Firm Fixed Price Delivery Order contract worth $6,681.60 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of 4563200640 - VRAYLAR 3 MG CAPSULE 30S. This award is part of the DLA Troop Support Medical's ECAT Generation V Program, a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 held by Dakota Drug, Inc. The contract has an ultimate completion date of January 2, 2024 and does not...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $12,932.87 firm fixed-price contract is for the delivery of VRAYLAR 1.5 MG CAPSULE 30S, a pharmaceutical product, with a performance period through May 6, 2024. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and healthcare equipment to support...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $22,846.43 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of VRAYLAR 6 MG CAPSULE 30S. This contract has a period of performance through December 4, 2024. Dakota Drug, Inc. is an established federal contractor, holding a significant Indefinite Delivery Contract (IDC) with the DLA's Troop Support Medical division, valued at...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract has a potential value of $4,889.89 and a completion date of December 22, 2023. Under this contract, Dakota Drug, Inc. will provide the DLA Troop Support Medical with VRAYLAR 6 MG CAPSULE 30S, a pharmaceutical product. This delivery order is issued against Dakota Drug's existing blanket purchase...
The Defense Logistics Agency (DLA) awarded a $12,321.87 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, to provide 4,565,219,647 units of the prescription drug Vraylar 6 mg capsule. This delivery order contract is part of a larger $999,999,999.00 single-award Indefinite Delivery Contract (IDC) with Dakota Drug, Inc. under the DLA Troop Support Medical's ECAT Generation V Program, which seeks to procure commercial medical equipment,...
This is a delivery order for $2,762.65 awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business. The order is for the pharmaceutical product Vraylar 4.5 mg capsule, with a performance period ending on April 9, 2024. The contract is a firm fixed-price arrangement without any set-aside designation. Dakota Drug, Inc. has over 20 years of experience as a prime contractor to the federal government, particularly the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract, with a ceiling value of $17,061.88, is for the delivery of the prescription medication Vraylar (1.5 mg capsule, 30 count) to support U.S. Armed Forces medical operations. The award is part of a larger Indefinite Delivery Contract (IDC) held by Dakota Drug, Inc.,...
  • SPE2DB24D8003
    Indefinite Delivery Contract
  • SPE2DB24D8003-SPE2DB25FJTUH
    Delivery Order

This federal contract award, identified as SPE2DB24D8003|SPE2DB25FJTUH, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,608.06, is a Firm Fixed Price Delivery Order for the provision of VRAYLAR 4.5 MG CAPSULE 30S, a pharmaceutical product.

The contract is not set aside and is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This IDC, which is part of the DLA Troop Support Medical's ECAT Generation V Program, allows Dakota Drug, Inc. to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations. The IDC has a performance period extending through December 31, 2025.

Generated 5/9/25, 9:44 AM